Jason Campbell - Chromadex Corp Senior Development
| CDXC Stock | USD 7.59 0.13 1.74% |
Executive
Jason Campbell is Senior Development of Chromadex Corp
| Address | 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024 |
| Phone | 310 388 6706 |
| Web | https://www.chromadex.com |
Chromadex Corp Management Efficiency
As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.17. At present, Chromadex Corp's Intangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 2.6 M, whereas Total Assets are forecasted to decline to about 28.4 M. Chromadex Corp's management efficiency ratios could be used to measure how well Chromadex Corp manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| Michael Naso | Century Therapeutics | N/A | |
| Erin OBoyle | Rezolute | N/A | |
| Nick MD | Century Therapeutics | N/A | |
| Morgan Conn | Century Therapeutics | 55 | |
| Ling Zhou | Adagene | N/A | |
| Douglas CPA | Century Therapeutics | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Pattie Chiang | Kezar Life Sciences | N/A | |
| Daron Evans | Rezolute | 50 | |
| Ami Knoefler | Adagene | N/A | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Neel Anand | Kezar Life Sciences | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| Dr MBA | Acrivon Therapeutics, Common | N/A | |
| Greg Mann | Nkarta Inc | N/A | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| David MS | Ikena Oncology | N/A | |
| Joe Tedrick | Kezar Life Sciences | N/A | |
| Michael Deperro | Rezolute | N/A | |
Management Performance
| Return On Equity | 0.0482 | ||||
| Return On Asset | 0.0051 |
Chromadex Corp Leadership Team
Elected by the shareholders, the Chromadex Corp's board of directors comprises two types of representatives: Chromadex Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chromadex. The board's role is to monitor Chromadex Corp's management team and ensure that shareholders' interests are well served. Chromadex Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chromadex Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kendall Knysch, Head Partnerships | ||
| Heather Blarcom, Senior Secretary | ||
| Brianna Gerber, Senior Director of FP&A, IR Contact Officer | ||
| Andrew Shao, Senior Affairs | ||
| Frank Jaksch, Co-Founder, CEO and President and Director | ||
| Chu Yan, Managing Pacific | ||
| Ozan CFA, CFO Officer | ||
| Robert Fried, Independent Director | ||
| James Lee, Principal CFO | ||
| David Kroes, Senior Matters | ||
| Jason Campbell, Senior Development | ||
| Michiko Kelley, Chief Officer | ||
| Alex Worsham, Vice Communications | ||
| Tom Shumaker, Managing Advisors | ||
| Fadi Karam, Chief Officer | ||
| Carlos Lopez, Senior Counsel |
Chromadex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chromadex Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0482 | ||||
| Return On Asset | 0.0051 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 540.47 M | ||||
| Shares Outstanding | 76.38 M | ||||
| Shares Owned By Insiders | 35.39 % | ||||
| Shares Owned By Institutions | 23.86 % | ||||
| Number Of Shares Shorted | 2.6 M | ||||
| Price To Earning | (19.51) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Chromadex Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chromadex Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chromadex Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chromadex Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chromadex Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For information on how to trade Chromadex Stock refer to our How to Trade Chromadex Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chromadex Corp. If investors know Chromadex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chromadex Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.02 | Revenue Per Share 1.215 | Quarterly Revenue Growth 0.312 | Return On Assets 0.0051 | Return On Equity 0.0482 |
The market value of Chromadex Corp is measured differently than its book value, which is the value of Chromadex that is recorded on the company's balance sheet. Investors also form their own opinion of Chromadex Corp's value that differs from its market value or its book value, called intrinsic value, which is Chromadex Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chromadex Corp's market value can be influenced by many factors that don't directly affect Chromadex Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chromadex Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Chromadex Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chromadex Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.